Open

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Study in Adult Participants With Ocular Myasthenia Gravi

Study is designed keeping in mind the high unmet medical need for an approved, safe, and effective treatment for patients with ocular MG

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At each visit subjects will be asked to complete questionnaires determining overall health, Mental health, MG symptoms and quality of life. Blood and urine samples will be collected and at certain visits 12 lead ECG will be performed besides complete MG and neurological assessment by the study doctor

Incentives

Travel reimibursement based on miles travelled for visit

In-person visits:
8 + dependent on MG disease progression

Total length of participation:
24 months

Looking for Specific Volunteers

Able to participate:

Ocular Myasthenia Gravis
confirmed diagnosis of MG

Not eligible if:

Pregnant
lactating
Severe MG

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Visit Study Website

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

James Howard
Neurology

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System

IRB Number

24-2989

ClinicalTrials.gov

later

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.